schizophrenia

Advantage BMS as AbbVie drug fails schizophrenia trials
Pharmaphorum
Mon, 11/11/24 - 11:24 am
AbbVie
emraclidine
schizophrenia
Cerevel Therapeutics
clinical trials
Bristol Myers Squibb
Teva’s long-lasting schizophrenia injectable shines in Phase III
Clinical Trials Arena
Mon, 11/4/24 - 07:02 pm
Teva Pharmaceutical
clinical trials
schizophrenia
TEV-479
For Bristol Myers Squibb's newly approved schizophrenia drug, what a long, strange trip it's been
Fierce Pharma
Mon, 10/7/24 - 11:16 am
Bristol Myers Squibb
KarXT
Cobenfy
schizophrenia
Bristol Myers Squibb wins FDA approval for first new schizophrenia drug in 30 years
Medical Marketing and Media
Mon, 09/30/24 - 09:28 am
Bristol Myers Squibb
FDA
schizophrenia
Cobenfy
FDA eyes first schizophrenia drug shift in decades
Axios
Thu, 09/26/24 - 11:02 am
Bristol Myers Squibb
FDA
KarXT
schizophrenia
Teva touts safety profile of once-monthly schizophrenia therapy
Clinical Trials Arena
Mon, 09/23/24 - 11:17 am
Teva Parmceuticals
TEV-749
Olanzapine
schizophrenia
Neurocrine's bid to save schizophrenia prospect fails
Fierce Biotech
Fri, 09/13/24 - 11:14 am
Neurocrine Biosciences
schizophrenia
clinical trials
luvadaxistat
3 FDA approval dates to watch in the year’s final push
Pharma Voice
Wed, 09/11/24 - 11:39 am
FDA
Bristol Myers Squibb
KarXT
schizophrenia
Regeneron
Sanofi
Dupixent
COPD
BridgeBio
acoramidis
ATTR cardiomyopathy
Neurocrine's drug cuts schizophrenia symptoms in mid-stage study
Reuters
Wed, 08/28/24 - 11:42 am
Neurocrine Biosciences
schizophrenia
clinical trials
NBI-1117568
BMS’ KarXT nears schizophrenia approval, but AbbVie and others wait in the wings
Pharma Voice
Mon, 08/19/24 - 09:58 am
Bristol Myers Squibb
KarXT
FDA
schizophrenia
AbbVie
5 Neuro Data Readouts to Watch in the Second Half of 2024
BioSpace
Mon, 07/15/24 - 11:43 am
neurology
clinical trials
Athira Pharma
fosgonimeton
Alzheimer's disease
AbbVie
Cerevel Therapeutics
emraclidine
schizophrenia
Neumora Therapeutics
major depressive disorder
navacaprant
Amylx
AMX003
Wolfram syndrome
Vigil Neuroscience
iluzanebart
5 FDA Decisions to Watch in the Second Half of 2024
BioSpace
Mon, 06/24/24 - 11:29 am
FDA
Eli Lilly
donanemab
Alzheimer's disease
Adaptimmune
afami-cel
advanced synovial sarcoma
Lykos Therapeutics
MDMA
PTSD
Bristol Myers Squibb
KarXT
schizophrenia
Daiichi Sankyo
AstraZeneca
Dato-DXd
non-small cell lung cancer
Teva, Medincell's schizophrenia drug succeeds in late-stage study
Yahoo/Reuters
Wed, 05/8/24 - 11:11 am
Teva Pharmaceutical
MedinCell
schizophrenia
clinical trials
TEV-749
As BMS announces major cuts, its Karuna deal looks poised to drive growth
Pharma Voice
Tue, 04/30/24 - 08:29 am
Karuna Therapeutics
schizophrenia
Bristol Myers Squibb
clinical trials
KarXT
Neumora's schizophrenia drug faces FDA hold over convulsions in rabbits
Fierce Biotech
Mon, 04/15/24 - 11:00 am
Neumora Therapeutics
schizophrenia
FDA
clinical trials
NMRA-266
Psychiatry drugs finally have pharma’s attention. Can they keep it?
BioPharma Dive
Tue, 04/9/24 - 05:50 pm
Karuna Therapeutics
schizophrenia
psychiatric disease
Bristol Myers' schizophrenia drug reduces symptoms without weight gain in late-stage studies
Reuters
Sun, 04/7/24 - 04:42 pm
Bristol Myers Squibb
schizophrenia
clinical trials
KarXT
Teva, Viatris win new chance to challenge J&J schizophrenia drug patent
Reuters
Mon, 04/1/24 - 12:04 pm
Teva Pharmaceutical
JNJ
Viatris
schizophrenia
patents
Invega Sustenna
Acadia’s schizophrenia drug trial fails to meet primary endpoint
Clinical Trials Arena
Tue, 03/12/24 - 11:20 am
Acadia Pharmaceuticals
clinical trials
schizophrenia
pimavanserin
Acadia Pharmaceuticals' schizophrenia drug fails in late-stage study
Reuters
Mon, 03/11/24 - 04:56 pm
Acadia Pharma
antipsychotics
clinical trials
schizophrenia

Pages